Surgical management of a locally advanced jejunal stromal tumor: A case report of a challenging condition

被引:0
作者
Hasnaoui, Anis [1 ,2 ]
Trigui, Racem [1 ,2 ]
Khedhiri, Nizar [1 ,3 ]
Helal, Imen [1 ,4 ]
Zaafouri, Haithem [1 ,3 ]
Ben Maamer, Anis [1 ,3 ]
机构
[1] Tunis El Manar Univ, Fac Med Tunis, Rue Djebal Lakhdar, Tunis 1006, Tunisia
[2] Menzel Bourguiba Hosp, Dept Gen Surg, Menzel Bourguiba, Tunisia
[3] Habib Thameur Hosp, Dept Gen Surg, Tunis, Tunisia
[4] Habib Thameur Hosp, Dept Pathol, Tunis, Tunisia
来源
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS | 2024年 / 114卷
关键词
Gastrointestinal stromal tumors; Jejunal neoplasms; Locally advanced; Protein kinase inhibitors; Case report; IMATINIB MESYLATE; SOFT-TISSUE; PHASE-II; DIAGNOSIS; RESECTION; ADJUVANT; SARCOMA; TRIAL;
D O I
10.1016/j.ijscr.2023.109155
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction and importance: Locally advanced jejunal stromal tumors stand as a captivating and relatively rare entity, garnering attention for several reasons. Their inaccessible location by conventional endoscopy poses a diagnostic challenge. Further, treatment decisions necessitate a multidisciplinary approach, compounded by the absence of high-level evidence studies.Case presentation: A 54-year-old patient was admitted to our surgical department with abdominal pain and chronic anemia. Abdominal CT imaging confirmed the presence of a non-metastatic sizable jejunal tumor. The patient underwent laparotomy, revealing a locally advanced jejunal tumor contracting the ileum and the ascending colon. A monobloc oncological resection was performed, followed by the restoration of digestive continuity. Anatomopathological analysis delineated a locally advanced Stromal Tumor with a high risk of recurrence. The patient underwent a course of tyrosine kinase inhibitors for 3 years, with no reported recurrence during the subsequent 3-year follow-up. Discussion: Locally advanced jejunal stromal tumors are rare. Most patients present with unspecific symptoms. Diagnosis remains challenging due to their intricate anatomical location. Decisions regarding management must be deliberated within a multidisciplinary framework, tailored to each patient's unique characteristics. While combined therapeutic modalities have demonstrated efficacy in recent studies, prudence is advised given the heightened incidence of both short and long-term complications.Conclusion: In the absence of randomized controlled trials, the management of locally advanced jejunal stromal tumors underscores the imperative of multidisciplinary collaboration in treatment deliberations. A wide, sometimes mutilating excision is only permissible if it is complete.
引用
收藏
页数:5
相关论文
共 20 条
  • [1] Ruptured gastro-intestinal stromal tumor as a surgical emergency: A case report and literature review
    Abdelgawad, Mohamed
    Kamel, Omar M.
    Issa, Peter P.
    Omar, Mahmoud
    Barghuthi, Lutfi
    Davis, Tyler
    Ismael, Hishaam
    [J]. JOURNAL OF SURGICAL CASE REPORTS, 2022, 2022 (11):
  • [2] The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines
    Agha, Riaz A.
    Franchi, Thomas
    Sohrabi, Catrin
    Mathew, Ginimol
    Kerwan, Ahmed
    Thoma, Achilles
    Beamish, Andrew J.
    Noureldin, Ashraf
    Rao, Ashwini
    Vasudevan, Baskaran
    Challacombe, Ben
    Perakath, Benjamin
    Kirshtein, Boris
    Ekser, Burcin
    Pramesh, C. S.
    Laskin, Daniel M.
    Machado-Aranda, David
    Miguel, Diana
    Pagano, Duilio
    Millham, Frederick H.
    Roy, Gaurav
    Kadioglu, Huseyin
    Nixon, Iain J.
    Mukhejree, Indraneil
    McCaul, James A.
    Ngu, James Chi-Yong
    Albrecht, Joerg
    Gomez Rivas, Juan
    Raveendran, Kandiah
    Derbyshire, Laura
    Ather, M. Hammad
    Thorat, Mangesh A.
    Valmasoni, Michele
    Bashashati, Mohammad
    Chalkoo, Mushtaq
    Teo, Nan Zun
    Raison, Nicholas
    Muensterer, Oliver J.
    Bradley, Patrick James
    Goel, Prabudh
    Pai, Prathamesh S.
    Afifi, Raafat Yahia
    Rosin, Richard David
    Coppola, Roberto
    Klappenbach, Roberto
    Wynn, Rolf
    De Wilde, Rudy Leon
    Surani, Salim
    Giordano, Salvatore
    Massarut, Samuele
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2020, 84 : 226 - 230
  • [3] Acute abdomen secondary to perforated jejunal gastrointestinal stromal tumor and imatinib-related isolated pericardial effusion in a 50-year-old female patient: A case report and review of literature
    Aldosari, Sarah
    Ayman, Azzam
    Almaiman, Loulwah
    Alzaid, Tariq
    Alhossaini, Rana
    Amin, Tarek
    [J]. INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2023, 106
  • [4] Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Casali, P. G.
    Blay, J. Y.
    Abecassis, N.
    Bajpai, J.
    Bauer, S.
    Biagini, R.
    Bielack, S.
    Bonvalot, S.
    Boukovinas, I
    Bovee, J. V. M. G.
    Boye, K.
    Brodowicz, T.
    Buonadonna, A.
    De Alava, E.
    Dei Tos, A. P.
    Del Muro, X. G.
    Dufresne, A.
    Eriksson, M.
    Fedenko, A.
    Ferraresi, V
    Ferrari, A.
    Frezza, A. M.
    Gasperoni, S.
    Gelderblom, H.
    Gouin, F.
    Grignani, G.
    Haas, R.
    Hassan, A. B.
    Hindi, N.
    Hohenberger, P.
    Joensuu, H.
    Jones, R. L.
    Jungels, C.
    Jutte, P.
    Kasper, B.
    Kawai, A.
    Kopeckova, K.
    Krakorova, D. A.
    Le Cesne, A.
    Le Grange, F.
    Legius, E.
    Leithner, A.
    Lopez-Pousa, A.
    Martin-Broto, J.
    Merimsky, O.
    Messiou, C.
    Miah, A. B.
    Mir, O.
    Montemurro, M.
    Morosi, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (01) : 20 - 33
  • [5] Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
    Casali, Paolo G.
    Le Cesne, Axel
    Velasco, Andres Poveda
    Kotasek, Dusan
    Rutkowski, Piotr
    Hohenberger, Peter
    Fumagalli, Elena
    Judson, Ian R.
    Italiano, Antoine
    Gelderblom, Hans
    Adenis, Antoine
    Hartmann, Jorg T.
    Duffaud, Florence
    Goldstein, David
    Broto, Javier M.
    Gronchi, Alessandro
    Dei Tos, Angelo P.
    Marreaud, Sandrine
    van der Graaf, Winette T.A.
    Zalcberg, John R.
    Litiere, Saskia
    Blay, Jean-Yves
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) : 4276 - 4283
  • [6] Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    DeMatteo, Ronald P.
    Ballman, Karla V.
    Antonescu, Cristina R.
    Maki, Robert G.
    Pisters, Peter W. T.
    Demetri, George D.
    Blackstein, Martin E.
    Blanke, Charles D.
    von Mehren, Margaret
    Brennan, Murray F.
    Patel, Shreyaskumar
    McCarter, Martin D.
    Polikoff, Jonathan A.
    Tan, Benjamin R.
    Owzar, Kouros
    [J]. LANCET, 2009, 373 (9669) : 1097 - 1104
  • [7] Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST
    Ding, Ping'an
    Guo, Honghai
    He, Xiaoxiao
    Sun, Chenyu
    Lowe, Scott
    Bentley, Rachel
    Zhou, Qin
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Yang, Li
    Zhao, Qun
    [J]. BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [8] A jejunal gastrointestinal stromal tumor with massive gastrointestinal hemorrhage treated by emergency surgery: A case report
    Jablonska, Beata
    Szmigiel, Pawel
    Wosiewicz, Piotr
    Baron, Jan
    Szczesny-Karczewska, Weronika
    Mrowiec, Slawomir
    [J]. MEDICINE, 2022, 101 (35) : E30098
  • [9] Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
    Joensuu, Heikki
    Eriksson, Mikael
    Hall, Kirsten Sundby
    Reichardt, Annette
    Hermes, Barbara
    Schuette, Jochen
    Cameron, Silke
    Hohenberger, Peter
    Jost, Philipp J.
    Al-Batran, Salah-Eddin
    Lindner, Lars H.
    Bauer, Sebastian
    Wardelmann, Eva
    Nilsson, Bengt
    Kallio, Raija
    Jaakkola, Panu
    Junnila, Jouni
    Alvegard, Thor
    Reichardt, Peter
    [J]. JAMA ONCOLOGY, 2020, 6 (08) : 1241 - 1246
  • [10] Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
    Kurokawa, Yukinori
    Yang, Han-Kwang
    Cho, Haruhiko
    Ryu, Min-Hee
    Masuzawa, Toru
    Park, Sook Ryun
    Matsumoto, Sohei
    Lee, Hyuk-Joon
    Honda, Hiroshi
    Kwon, Oh Kyoung
    Ishikawa, Takashi
    Lee, Kyung Hee
    Nabeshima, Kazuhito
    Kong, Seong-Ho
    Shimokawa, Toshio
    Yook, Jeong-Hwan
    Doki, Yuichiro
    Im, Seock-Ah
    Hirota, Seiichi
    Hahn, Seokyung
    Nishida, Toshirou
    Kang, Yoon-Koo
    [J]. BRITISH JOURNAL OF CANCER, 2017, 117 (01) : 25 - 32